Epirubicin, paclitaxel and CMF as adjuvant treatment in node positive patients with operable breast cancer. Safety analysis of a randomized phase III study comparing two dose-dense sequential regimens.

被引：0
|
作者：
Fountzilas, G [1 ]
Gogas, H [1 ]
Papadimitriou, CH [1 ]
Kalofonos, HP [1 ]
Tsavdaridis, D [1 ]
Christodoulou, CH [1 ]
Briasoulis, E [1 ]
Bafaloukos, D [1 ]
Karina, M [1 ]
Markopoulos, CH [1 ]
Pectasides, D [1 ]
Karapanagiotis, K [1 ]
Papakostas, P [1 ]
Aravantinos, G [1 ]
Kosmidis, P [1 ]
Stathopoulos, GP [1 ]
Dimopoulos, AM [1 ]
机构：
[1] Data Off, Athens, Greece
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2005年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S108 / S108
页数：1
相关论文
共 50 条
  • [41] Adjuvant phase III trial comparing an intensified dose-dense adjuvant therapy with EnPC compared to a dose-dense, dose-adapted therapy with dtEC-dtD in patients with primary high risk breast cancer
    Noeding, S.
    Forstbauer, H.
    Wachsmann, G.
    Ober, A.
    Schneeweiss, A.
    Christensen, B.
    von Abel, E.
    Grischke, E-M
    Hoeffkes, H-G
    Klare, P.
    Ko, Y-D
    Schmatloch, S.
    Burchardi, N.
    Loibl, S.
    von Minckwitz, G.
    Moebus, V
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 111 - 112
  • [42] Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide:: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma
    Fornier, MN
    Seidman, AD
    Theodoulou, M
    Moynahan, ME
    Currie, V
    Moasser, M
    Sklarin, N
    Gilewski, T
    D'Andrea, G
    Salvaggio, R
    Panageas, KS
    Norton, L
    Hudis, C
    CLINICAL CANCER RESEARCH, 2001, 7 (12) : 3934 - 3941
  • [43] Epirubicin and paclitaxel with G-CSF support in first line metastatic breast cancer: a randomized phase II study of dose-dense and dose-escalated chemotherapy
    R. I. Lalisang
    F. L. G. Erdkamp
    C. J. Rodenburg
    C. T. A. M. Knibbeler-van Rossum
    J. W. R. Nortier
    A. van Bochove
    P. H. Th. J. Slee
    E. E. Voest
    J. A. Wils
    J. Wals
    O. J. L. Loosveld
    A. E. M. Smals
    G. H. Blijham
    V. C. G. Tjan-Heijnen
    H. C. Schouten
    Breast Cancer Research and Treatment, 2011, 128 : 437 - 445
  • [44] Epirubicin and paclitaxel with G-CSF support in first line metastatic breast cancer: a randomized phase II study of dose-dense and dose-escalated chemotherapy
    Lalisang, R. I.
    Erdkamp, F. L. G.
    Rodenburg, C. J.
    Knibbeler-van Rossum, C. T. A. M.
    Nortier, J. W. R.
    van Bochove, A.
    Slee, P. H. Th. J.
    Voest, E. E.
    Wils, J. A.
    Wals, J.
    Loosveld, O. J. L.
    Smals, A. E. M.
    Blijham, G. H.
    Tjan-Heijnen, V. C. G.
    Schouten, H. C.
    BREAST CANCER RESEARCH AND TREATMENT, 2011, 128 (02) : 437 - 445
  • [45] Efficacy, safety and proper dose analysis of PEGylated granulocyte colony-stimulating factor as support for dose-dense adjuvant chemotherapy in node positive Chinese breast cancer patients
    Zhang, Fan
    LingHu, RuiXia
    Zhan, XingYang
    Li, Ruisheng
    Feng, Fan
    Gao, Xudong
    Zhao, Lei
    Yang, Junlan
    ONCOTARGET, 2017, 8 (45) : 80020 - 80028
  • [46] A Phase II Trial of Dose-Dense Neoadjuvant Gemcitabine, Epirubicin, and Albumin-Bound Paclitaxel With Pegfilgrastim in the Treatment of Patients With Locally Advanced Breast Cancer
    Yardley, Denise A.
    Zubkus, John
    Daniel, Brooke
    Inhorn, Roger
    Lane, Cassie M.
    Vazquez, Elizabeth R.
    Naot, Yuval
    Burris, Howard A., III
    Hainsworth, John D.
    CLINICAL BREAST CANCER, 2010, 10 (05) : 367 - 372
  • [47] Randomized phase II adjuvant trial of dose-dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node-positive breast cancer
    Puhalla, Shannon
    Mrozek, Ewa
    Young, Donn
    Ottman, Susan
    McVey, Anne
    Kendra, Kari
    Merriman, Nancy J.
    Knapp, Mark
    Patel, Taral
    Thompson, Mark E.
    Maher, James F.
    Moore, Timothy D.
    Shapiro, Charles L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) : 1691 - 1697
  • [48] Sequential dose-dense epirubicin/paclitaxel (E-T) with G-CSF support compared to standard EC-T (epirubicin/cyclophosphamide followed by paclitaxel) for patients with operable breast cancer and 1-3 positive lymph nodes - first toxicity analysis.
    Eggemann, H
    Krocker, J
    Kuemmel, S
    Ulm, K
    Zeiser, T
    Kreienberg, R
    Budner, M
    Lichtenegger, W
    Renziehausen, K
    Koelbl, H
    Kohls, A
    Morack, G
    Koehler, U
    Emons, G
    Breitbach, GP
    Elling, D
    BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S159 - S159
  • [49] Intense Dose-Dense Sequential Chemotherapy With Epirubicin, Paclitaxel, and Cyclophosphamide Compared With Conventionally Scheduled Chemotherapy in High-Risk Primary Breast Cancer: Mature Results of an AGO Phase III Study
    Moebus, Volker
    Jackisch, Christian
    Lueck, Hans-Joachim
    du Bois, Andreas
    Thomssen, Christoph
    Kurbacher, Christian
    Kuhn, Walther
    Nitz, Ulrike
    Schneeweiss, Andreas
    Huober, Jens
    Harbeck, Nadia
    von Minckwitz, Gunter
    Runnebaum, Ingo B.
    Hinke, Axel
    Kreienberg, Rolf
    Konecny, Gottfried E.
    Untch, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (17) : 2874 - 2880
  • [50] Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer
    Piccart, MJ
    Di Leo, A
    Beauduin, M
    Vindevoghel, A
    Michel, J
    Focan, C
    Tagnon, A
    Ries, F
    Gobert, P
    Finet, C
    Closon-Dejardin, MT
    Dufrane, JP
    Kerger, J
    Liebens, F
    Beauvois, S
    Bartholomeus, S
    Dolci, S
    Lobelle, JP
    Paesmans, M
    Nogaret, JM
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (12) : 3103 - 3110
12345